111 related articles for article (PubMed ID: 37833852)
1. Identification and validation of microtubule depolymerizing agent, CYT997, as a potential drug candidate for hepatocellular carcinoma.
Ahmad F; Ma L; Wei W; Liu Y; Hakim I; Daugherty A; Mujahid S; Radin AA; Chua MS; So S
Liver Int; 2023 Dec; 43(12):2794-2807. PubMed ID: 37833852
[TBL] [Abstract][Full Text] [Related]
2. Both glypican-3/Wnt/β-catenin signaling pathway and autophagy contributed to the inhibitory effect of curcumin on hepatocellular carcinoma.
Hu P; Ke C; Guo X; Ren P; Tong Y; Luo S; He Y; Wei Z; Cheng B; Li R; Luo J; Meng Z
Dig Liver Dis; 2019 Jan; 51(1):120-126. PubMed ID: 30001951
[TBL] [Abstract][Full Text] [Related]
3. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
[TBL] [Abstract][Full Text] [Related]
4. Role of Glypican-3 in the growth, migration and invasion of primary hepatocytes isolated from patients with hepatocellular carcinoma.
Montalbano M; Rastellini C; McGuire JT; Prajapati J; Shirafkan A; Vento R; Cicalese L
Cell Oncol (Dordr); 2018 Apr; 41(2):169-184. PubMed ID: 29204978
[TBL] [Abstract][Full Text] [Related]
5. Propofol-induced miR-219-5p inhibits growth and invasion of hepatocellular carcinoma through suppression of GPC3-mediated Wnt/β-catenin signalling activation.
Gong T; Ning X; Deng Z; Liu M; Zhou B; Chen X; Huang S; Xu Y; Chen Z; Luo R
J Cell Biochem; 2019 Oct; 120(10):16934-16945. PubMed ID: 31104336
[TBL] [Abstract][Full Text] [Related]
6. HOXA-AS2 Promotes Proliferation and Induces Epithelial-Mesenchymal Transition via the miR-520c-3p/GPC3 Axis in Hepatocellular Carcinoma.
Zhang Y; Xu J; Zhang S; An J; Zhang J; Huang J; Jin Y
Cell Physiol Biochem; 2018; 50(6):2124-2138. PubMed ID: 30415263
[TBL] [Abstract][Full Text] [Related]
7. Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-β2.
Sun CK; Chua MS; He J; So SK
Neoplasia; 2011 Aug; 13(8):735-47. PubMed ID: 21847365
[TBL] [Abstract][Full Text] [Related]
8. Human Monoclonal Antibody Targeting the Heparan Sulfate Chains of Glypican-3 Inhibits HGF-Mediated Migration and Motility of Hepatocellular Carcinoma Cells.
Gao W; Kim H; Ho M
PLoS One; 2015; 10(9):e0137664. PubMed ID: 26332121
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy.
Gao W; Kim H; Feng M; Phung Y; Xavier CP; Rubin JS; Ho M
Hepatology; 2014 Aug; 60(2):576-87. PubMed ID: 24492943
[TBL] [Abstract][Full Text] [Related]
10. Long non-coding RNA FENDRR inhibits proliferation and invasion of hepatocellular carcinoma by down-regulating glypican-3 expression.
Wang B; Xian J; Zang J; Xiao L; Li Y; Sha M; Shen M
Biochem Biophys Res Commun; 2019 Jan; 509(1):143-147. PubMed ID: 30573358
[TBL] [Abstract][Full Text] [Related]
11. Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma.
Deng L; Sun J; Chen X; Liu L; Wu D
J Exp Clin Cancer Res; 2019 Jul; 38(1):316. PubMed ID: 31319849
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial ROS accumulation inhibiting JAK2/STAT3 pathway is a critical modulator of CYT997-induced autophagy and apoptosis in gastric cancer.
Cao Y; Wang J; Tian H; Fu GH
J Exp Clin Cancer Res; 2020 Jun; 39(1):119. PubMed ID: 32576206
[TBL] [Abstract][Full Text] [Related]
13. Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo.
Wei W; Chua MS; Grepper S; So S
Int J Cancer; 2010 May; 126(10):2426-36. PubMed ID: 19662654
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-133b inhibits hepatocellular carcinoma cell progression by targeting Sirt1.
Tian Z; Jiang H; Liu Y; Huang Y; Xiong X; Wu H; Dai X
Exp Cell Res; 2016 May; 343(2):135-147. PubMed ID: 27090017
[TBL] [Abstract][Full Text] [Related]
15. Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44+ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma.
Toh TB; Lim JJ; Hooi L; Rashid MBMA; Chow EK
J Hepatol; 2020 Jan; 72(1):104-118. PubMed ID: 31541681
[TBL] [Abstract][Full Text] [Related]
16. EPHB2 Activates β-Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma.
Leung HW; Leung CON; Lau EY; Chung KPS; Mok EH; Lei MML; Leung RWH; Tong M; Keng VW; Ma C; Zhao Q; Ng IOL; Ma S; Lee TK
Cancer Res; 2021 Jun; 81(12):3229-3240. PubMed ID: 33903122
[TBL] [Abstract][Full Text] [Related]
17. miR-4510 blocks hepatocellular carcinoma development through RAF1 targeting and RAS/RAF/MEK/ERK signalling inactivation.
Ghousein A; Mosca N; Cartier F; Charpentier J; Dupuy JW; Raymond AA; Bioulac-Sage P; Grosset CF
Liver Int; 2020 Jan; 40(1):240-251. PubMed ID: 31612616
[TBL] [Abstract][Full Text] [Related]
18. Long noncoding RNA glypican 3 (GPC3) antisense transcript 1 promotes hepatocellular carcinoma progression via epigenetically activating GPC3.
Zhu XT; Yuan JH; Zhu TT; Li YY; Cheng XY
FEBS J; 2016 Oct; 283(20):3739-3754. PubMed ID: 27573079
[TBL] [Abstract][Full Text] [Related]
19. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
20. The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation.
Lai JP; Oseini AM; Moser CD; Yu C; Elsawa SF; Hu C; Nakamura I; Han T; Aderca I; Isomoto H; Garrity-Park MM; Shire AM; Li J; Sanderson SO; Adjei AA; Fernandez-Zapico ME; Roberts LR
Hepatology; 2010 Nov; 52(5):1680-9. PubMed ID: 20725905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]